<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989208</url>
  </required_header>
  <id_info>
    <org_study_id>SG1002-001</org_study_id>
    <nct_id>NCT01989208</nct_id>
  </id_info>
  <brief_title>Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients</brief_title>
  <official_title>A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sulfagenix Australia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sulfagenix Australia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with heart failure are reported to have lower levels of hydrogen sulfide in their&#xD;
      blood, even though sulfur is available naturally in the diet. Hydrogen sulfide is a molecule&#xD;
      that has been shown to have a number of beneficial effects and thus the low levels may&#xD;
      contribute to the disease. This trial is testing whether a medical food product of synthetic&#xD;
      sulfur molecules, SG1002, can overcome this deficit in blood levels of hydrogen sulfide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with heart failure have been shown to have a deficit in circulating hydrogen sulfide&#xD;
      levels, which, since sulfur is not readily bioavailable and is declining in food substances,&#xD;
      cannot be treated adequately by diet alone. This deficit in circulating hydrogen sulfide is&#xD;
      thought to lead to increases in oxidative stress and with this, associated problems that can&#xD;
      contribute to heart failure. This is a study to evaluate the safety and ability of multiple&#xD;
      doses of oral SG1002 in subjects with heart failure to reverse the deficits in circulating&#xD;
      hydrogen sulfide. The primary objective is to assess the safety and the ability of multiple&#xD;
      doses of twice daily administration of SG1002 compared with placebo to increase circulating&#xD;
      levels of hydrogen sulfide. Initially, a dose escalation study will be carried out for 21&#xD;
      days in 4 normal subjects, randomized 3:1 active:placebo. Subjects will receive a 200 mg dose&#xD;
      BID for 7 days and in no adverse events, escalate to 400 mg for 7 days then 800 mg for 7&#xD;
      days. Safety parameters will be assessed for each dose, along with pharmacokinetic analysis&#xD;
      and markers of oxidative stress and heart failure. Following completion of the normal healthy&#xD;
      subjects, 10 heart failure subjects will be randomized 4:1 active:placebo and tested as&#xD;
      described above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>Following 7 days of treatment at each of three doses</time_frame>
    <description>The number of subjects reporting Treatment Emergent Adverse Events at any time during the study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing Changes in Peak Hydrogen Sulfide Levels in Heart Failure Subjects Following SG1002 Administration.</measure>
    <time_frame>24 hours</time_frame>
    <description>At the start of each dose, blood samples will be obtained and circulating hydrogen sulfide levels will be assessed over a 24 hour period to determine whether SG1002 can overcome the deficits reported in heart failure patients. Peak hydrogen sulfide levels were measured during the first 4 hours post-administration when maximum concentrations of hydrogen sulfide were reached.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessing Potential Clinical Benefits of SG1002 Administration by Analyzing BNP Levels.</measure>
    <time_frame>7 days at each dose.</time_frame>
    <description>BNP levels were measured for the each subject prior to treatment and after 7 days on each treatment dose, thus representing a change in BNP over the 21 day treatment period. Increased BNP levels are associated with worsening heart failure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sugar capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SG1002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SG1002</intervention_name>
    <description>200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.</description>
    <arm_group_label>SG1002</arm_group_label>
    <other_name>alpha sulfur/sodium sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.</description>
    <arm_group_label>Sugar capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (healthy volunteers):&#xD;
&#xD;
          -  Healthy male volunteers aged between 18 and 45 years (inclusive);&#xD;
&#xD;
          -  Body mass index between 19 and 30 kg/m^2 (inclusive);&#xD;
&#xD;
          -  No clinically significant findings in the medical history and physical examination;&#xD;
&#xD;
          -  No clinically significant laboratory values and urinalysis, unless the investigator&#xD;
             considers any abnormality to be clinically irrelevant;&#xD;
&#xD;
          -  Normal ECG, blood pressure and heart rate, unless the Investigator considers any&#xD;
             abnormality to be not clinically significant (NCS);&#xD;
&#xD;
          -  Willing to use contraception (single barrier methods); and&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria (healthy volunteers):&#xD;
&#xD;
          -  Have received blood products within 1 month prior to Screening;&#xD;
&#xD;
          -  Have received any investigational research agent within 30 days or 5 half-lives&#xD;
             (whichever is longer) prior to the first dose of trial medical food;&#xD;
&#xD;
          -  Have received an investigational vaccine within 6 months, a live attenuated vaccine&#xD;
             within 60 days or a registered vaccine within 30 days prior to the first dose of the&#xD;
             trial medical food;&#xD;
&#xD;
          -  Have a history of thyroidectomy or thyroid disease that required medication within the&#xD;
             past 12 months;&#xD;
&#xD;
          -  Have had serious angioedema episodes within the previous 3 years or requiring&#xD;
             medication in the previous two years;&#xD;
&#xD;
          -  Have a bleeding disorder diagnosed by a doctor (for example factor deficiency,&#xD;
             coagulopathy, or platelet disorder requiring special precautions) or significant&#xD;
             bruising or bleeding difficulties during blood draws;&#xD;
&#xD;
          -  Have a psychiatric condition that precludes compliance with the protocol, past or&#xD;
             present psychoses, past or present bipolar disorder, or a disorder requiring lithium,&#xD;
             within five years prior to enrolment;&#xD;
&#xD;
          -  Has a history of suicide plan;&#xD;
&#xD;
          -  Any clinically significant abnormality at Screening determined by medical history,&#xD;
             physical examination, blood chemistry, haematology, urinalysis and a 12-lead ECG, or&#xD;
             positive urine screen for drugs of abuse;&#xD;
&#xD;
          -  Any other condition which in the view of the Investigator is likely to interfere with&#xD;
             the study or put the subject at risk;&#xD;
&#xD;
          -  HIV, or hepatitis B or C positive;&#xD;
&#xD;
          -  Have a history of or current clinically significant gastrointestinal, hepatic, renal,&#xD;
             cardiovascular, respiratory, endocrine, oncological, immunodeficiency, neurological,&#xD;
             metabolic, haematological or autoimmune disorder;&#xD;
&#xD;
          -  Have a history of or current tuberculosis, epilepsy, diabetes or glaucoma;&#xD;
&#xD;
          -  Have clinical signs of active infection or a temperature more than 38.0°C at the time&#xD;
             of screening. Study entry may be deferred at the discretion of the Principal&#xD;
             Investigator;&#xD;
&#xD;
          -  Have evidence of drug or alcohol abuse;&#xD;
&#xD;
          -  Be unable to provide repeated blood samples without undue trauma or distress;&#xD;
&#xD;
          -  Anticipate surgery within the trial period; or&#xD;
&#xD;
          -  Inability to speak English (due to need to administer standardized English-language&#xD;
             questionnaire).&#xD;
&#xD;
        Inclusion Criteria (heart failure subjects):&#xD;
&#xD;
          -  Aged between 35 and 85 years (inclusive);&#xD;
&#xD;
          -  Has symptomatic heart failure, with New York Heart Association (NYHA)classification of&#xD;
             II or III;&#xD;
&#xD;
          -  Ambulatory;&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 40%;&#xD;
&#xD;
          -  Congestive heart failure has been stable for the previous 3 months (defined by no&#xD;
             change in baseline therapy or symptoms of heart failure for the previous 3 months);&#xD;
             and&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria (heart failure subjects):&#xD;
&#xD;
          -  Subject is pregnant or breastfeeding;&#xD;
&#xD;
          -  If female, the subject is either post-menopausal or surgically sterilised or willing&#xD;
             to use an acceptable method of birth control (i.e., a hormonal contraceptive,&#xD;
             intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence)&#xD;
             from signing of the informed consent form though to the Final Visit/Early Termination&#xD;
             Visit;&#xD;
&#xD;
          -  Myocardial infarction, unstable angina, stroke, cerebrovascular accident, percutaneous&#xD;
             coronary intervention, open heart surgery or transient ischemic attack (TIA) within 3&#xD;
             months prior to Screening;&#xD;
&#xD;
          -  Current symptomatic hypotension (defined as systolic blood pressure (SBP) ≤ 90 mmHg or&#xD;
             diastolic blood pressure (DBP) ≤ 40 mmHg);&#xD;
&#xD;
          -  Poorly controlled hypertension (defined as SBP ≥ 160 mmHg or DBP ≥ 100 mmHg) despite&#xD;
             therapy&#xD;
&#xD;
          -  Subjects with NYHA grade IV heart failure;&#xD;
&#xD;
          -  Subjects awaiting percutaneous coronary intervention or open heart surgery;&#xD;
&#xD;
          -  Subjects with serious liver disease;&#xD;
&#xD;
          -  Subjects with liver function test results three times the upper limit of normal.&#xD;
&#xD;
          -  Any change in cardiovascular drug therapy within three months prior to randomization&#xD;
&#xD;
          -  History of chronic obstructive pulmonary disease (diagnosed using GOLD criteria) or&#xD;
             evidence of restrictive lung disease (defined as forced expiratory volume (FEV1) to&#xD;
             forced vital capacity (FCV) ratio of &gt; 80%);&#xD;
&#xD;
          -  Poorly controlled diabetes (defined as HbA1c &gt; 10.0 %);&#xD;
&#xD;
          -  Has undergone Cardiac Resynchronisation Therapy (CRT) in the last 6 months and no&#xD;
             planned CRT;&#xD;
&#xD;
          -  Implantable cardioverter defibrillator (ICD) implant planned during the study;&#xD;
&#xD;
          -  Hypersensitivity to sulfur or related compounds;&#xD;
&#xD;
          -  Renal insufficiency defined as estimated Glomerular Filtration Rate (eGFR) &lt; 30&#xD;
             mL/minute/1.73 m2 (Modification of Diet in Renal Disease Study MDRD) [2];&#xD;
&#xD;
          -  Life expectancy less than 6 months;&#xD;
&#xD;
          -  Active malignancy requiring active anti-neoplastic therapy that will, in the opinion&#xD;
             of the investigator, interfere with study treatment or participation. (Stable basal&#xD;
             cell skin cancer and cancers being treated solely with hormonal therapy are allowed.)&#xD;
&#xD;
          -  Inability to speak English (due to need to administer standardized English-language&#xD;
             questionnaire); or&#xD;
&#xD;
          -  Any other chronic illness that may, in the opinion of the Investigator, increase the&#xD;
             risks associated with this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Lickliter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Krum, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <results_first_submitted>May 28, 2015</results_first_submitted>
  <results_first_submitted_qc>April 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Hydrogen Sulfide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugar Capsule</title>
          <description>Two normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.</description>
        </group>
        <group group_id="P2">
          <title>SG1002</title>
          <description>200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)&#xD;
SG1002: 200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days to six normal healthy subjects and six heart failure subjects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>200 mg (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>400 mg (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>800 mg (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Capsule</title>
          <description>Two normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.</description>
        </group>
        <group group_id="B2">
          <title>SG1002</title>
          <description>200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)&#xD;
SG1002: 200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.&#xD;
Six normal healthy subject and six heart failure subjects will be randomized and given SG1002 throughout the trial period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Normal Healthy Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" lower_limit="27" upper_limit="27"/>
                    <measurement group_id="B2" value="27.7" lower_limit="25" upper_limit="34"/>
                    <measurement group_id="B3" value="27.5" lower_limit="25" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.0" lower_limit="68" upper_limit="78"/>
                    <measurement group_id="B2" value="75.5" lower_limit="71" upper_limit="85"/>
                    <measurement group_id="B3" value="74.9" lower_limit="68" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Condition</title>
          <description>Heart Failure subjects were classified as NYHA Class II (Mild symptoms, including mild shortness of breath and/or angina) and slight limitation during ordinary activity) or III (Moderate symptoms, including marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances.Comfortable only at rest.)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal Healthy Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>The number of subjects reporting Treatment Emergent Adverse Events at any time during the study period.</description>
        <time_frame>Following 7 days of treatment at each of three doses</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Capsule</title>
            <description>Two normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.</description>
          </group>
          <group group_id="O2">
            <title>SG1002</title>
            <description>200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)&#xD;
SG1002: 200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.&#xD;
Six normal healthy subject and six heart failure subjects will be randomized and given SG1002 throughout the trial period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>The number of subjects reporting Treatment Emergent Adverse Events at any time during the study period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with Treatment Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with no Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessing Changes in Peak Hydrogen Sulfide Levels in Heart Failure Subjects Following SG1002 Administration.</title>
        <description>At the start of each dose, blood samples will be obtained and circulating hydrogen sulfide levels will be assessed over a 24 hour period to determine whether SG1002 can overcome the deficits reported in heart failure patients. Peak hydrogen sulfide levels were measured during the first 4 hours post-administration when maximum concentrations of hydrogen sulfide were reached.</description>
        <time_frame>24 hours</time_frame>
        <population>Heart failure subject (n=6) had baseline levels of hydrogen sulfide recorded at 0, 0.5, 1, 2, 4, 6, 12 and 24 hours after the administration of the first dose of each of the escalating doses of SG1002.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Baseline levels of free hydrogen sulfide (H2S) were recorded in heart failure subjects.</description>
          </group>
          <group group_id="O2">
            <title>200 mg SG1002</title>
            <description>200 mg capsules of SG1002 were administered BID for 7 days to heart failure subjects.</description>
          </group>
          <group group_id="O3">
            <title>400 mg SG002</title>
            <description>400 mg capsules of SG1002 were administered BID for 7 days to heart failure subjects.</description>
          </group>
          <group group_id="O4">
            <title>800 mg SG1002</title>
            <description>800 mg capsules of SG1002 were administered BID for 7 days to heart failure subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessing Changes in Peak Hydrogen Sulfide Levels in Heart Failure Subjects Following SG1002 Administration.</title>
          <description>At the start of each dose, blood samples will be obtained and circulating hydrogen sulfide levels will be assessed over a 24 hour period to determine whether SG1002 can overcome the deficits reported in heart failure patients. Peak hydrogen sulfide levels were measured during the first 4 hours post-administration when maximum concentrations of hydrogen sulfide were reached.</description>
          <population>Heart failure subject (n=6) had baseline levels of hydrogen sulfide recorded at 0, 0.5, 1, 2, 4, 6, 12 and 24 hours after the administration of the first dose of each of the escalating doses of SG1002.</population>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.05"/>
                    <measurement group_id="O2" value="0.44" spread="0.04"/>
                    <measurement group_id="O3" value="0.50" spread="0.08"/>
                    <measurement group_id="O4" value="0.51" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessing Potential Clinical Benefits of SG1002 Administration by Analyzing BNP Levels.</title>
        <description>BNP levels were measured for the each subject prior to treatment and after 7 days on each treatment dose, thus representing a change in BNP over the 21 day treatment period. Increased BNP levels are associated with worsening heart failure.</description>
        <time_frame>7 days at each dose.</time_frame>
        <population>Levels of BNP were recorded at baseline and every 7 days in the placebo group or the SG1002 dose escalation group.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Capsule: Day 0</title>
            <description>Baseline BNP levels of the subjects receiving sugar capsules.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Capsules: Day 7</title>
            <description>Baseline BNP levels of the subjects receiving sugar capsules for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Sugar Capsules: Day 14</title>
            <description>Baseline BNP levels of the subjects receiving sugar capsules for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Sugar Capsules: Day 21</title>
            <description>Baseline BNP levels of the subjects receiving sugar capsules for 21 days.</description>
          </group>
          <group group_id="O5">
            <title>SG1002: Day 0</title>
            <description>Baseline BNP levels of the subjects who were randomized to the SG1002 treatment group, prior to any drug administration.</description>
          </group>
          <group group_id="O6">
            <title>SG1002: Day 7</title>
            <description>Baseline BNP levels of the subjects who were randomized to the SG1002 treatment group, following administration of 200 mg SG1002 BID for 7 days.</description>
          </group>
          <group group_id="O7">
            <title>SG1002: Day 14</title>
            <description>Baseline BNP levels of the subjects who were randomized to the SG1002 treatment group, following administration of 200 mg SG1002 BID for 7 days, then 400 mg SG1002 BID for an additional 7 days.</description>
          </group>
          <group group_id="O8">
            <title>SG1002: Day 21</title>
            <description>Baseline BNP levels of the subjects who were randomized to the SG1002 treatment group, following administration of 200 mg SG1002 BID for 7 days, then 400 mg SG1002 BID for an additional 7 days and then 800 mg SG1002 BID for an additional 7 days..</description>
          </group>
        </group_list>
        <measure>
          <title>Assessing Potential Clinical Benefits of SG1002 Administration by Analyzing BNP Levels.</title>
          <description>BNP levels were measured for the each subject prior to treatment and after 7 days on each treatment dose, thus representing a change in BNP over the 21 day treatment period. Increased BNP levels are associated with worsening heart failure.</description>
          <population>Levels of BNP were recorded at baseline and every 7 days in the placebo group or the SG1002 dose escalation group.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="49.0"/>
                    <measurement group_id="O2" value="123.0" spread="72.0"/>
                    <measurement group_id="O3" value="156.5" spread="97.5"/>
                    <measurement group_id="O4" value="149.5" spread="53.5"/>
                    <measurement group_id="O5" value="77.5" spread="30.5"/>
                    <measurement group_id="O6" value="69.8" spread="26.9"/>
                    <measurement group_id="O7" value="79.0" spread="31.6"/>
                    <measurement group_id="O8" value="72.0" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugar Capsule</title>
          <description>Two normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.</description>
        </group>
        <group group_id="E2">
          <title>SG1002</title>
          <description>200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)&#xD;
SG1002: 200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.&#xD;
Six normal healthy subject and six heart failure subjects will be randomized and given placebo throughout the trial period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lethargy/syncope/diahrrea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Track Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Technical problems in measuring free H2S levels due to sample stability made assessment of PK difficult.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>President and CEO</name_or_title>
      <organization>Sulfagenix</organization>
      <phone>1-318-349-3851</phone>
      <email>tgiordano@sulfagenix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

